Table 1. Baseline characteristics of breast cancer cohort (n = 44).
| Variables | Number | % |
|---|---|---|
| Age (years) | ||
| < 60 | 23 | 52.3 |
| ≥ 60 | 21 | 47.7 |
| BMI | ||
| < 25 | 30 | 68.2 |
| ≥ 25 | 14 | 31.8 |
| Pathologic T stage | ||
| T1 | 18 | 40.9 |
| T2 | 21 | 47.7 |
| T3 | 5 | 11.4 |
| Pathologic N stage | ||
| N0 | 40 | 90.9 |
| N1 | 4 | 9.1 |
| Estrogen receptor status | ||
| Negative | 10 | 22.7 |
| Positive | 34 | 77.3 |
| Progesterone receptor status | ||
| Negative | 16 | 36.4 |
| Positive | 28 | 63.6 |
| HER2 status | ||
| Negative | 29 | 65.9 |
| Positive | 15 | 34.1 |
| Ki-67 index | ||
| <15% | 23 | 52.3 |
| 15%-30% | 12 | 27.2 |
| >30% | 9 | 20.5 |
| Nuclear grade | ||
| 1 | 24 | 54.5 |
| 2 | 9 | 20.5 |
| 3 | 11 | 25 |
BMI, body mass index; HER2, human epidermal growth factor receptor 2.